Verification of Imaging System PCD-1000A
- Conditions
- Cancer Patients
- Interventions
- Device: PET/CT imaging
- Registration Number
- NCT04024748
- Lead Sponsor
- Canon Medical Systems, USA
- Brief Summary
Scope Verification of technologies included in the PCD-1000A PET/CT imaging chain.
* Define and confirm all supported clinical protocols
* Evaluate performance
- Detailed Description
The study aim is system verification and associated software. Clinical data and clinical feedback will be used for verification.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 24
- Patients already scheduled for an FDG test at SDMI
- 40 years and older
- Capable of providing their informed consent
- Patients not scheduled for an FDG test at SDMI
- 39 years or younger
- Adult female patients that are and/or could become pregnant
- Not capable of providing their informed consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Patients already scheduled for a FDG test PET/CT imaging Subjects will be selected from patients already scheduled for a routine FDG PET/CT test. Only adult patients, 40 years old or older, capable of providing their informed consent, will be selected. Any adult female patients that are pregnant and/or could become pregnant will be excluded. Twenty patients will be recruited.
- Primary Outcome Measures
Name Time Method Confirm that PCD-1000A PET/CT System is Effective for Its Intended Use 3 months PCD-1000A PET/CT system's performance will be evaluated for oncology PET imaging on cancer patients to verify that the system performs as expected.
• Verify that all supported clinical protocols from PET acquisition, reconstruction, to presentation (filtering) perform as expected. Images acquired by PCD-1000A PET/CT will be compared with images acquired during a standard-of-care PET/CT scan by a commercially available PET/CT system just prior to imaging with the PCD-1000A PET/CT System. Image quality evaluation will include assessment of uniformity of the liver, delineation of the lungs, presence of artifacts and using Likert scale.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Steinberg Diagnostic Medical Imaging Centers
🇺🇸Henderson, Nevada, United States